Cite
HARVARD Citation
Sandborn, W. et al. (2015). Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study. Alimentary pharmacology & therapeutics. 42 (3), pp. 330-342. [Online].